Nat Biotechnol. concordant between HER2 and F1CDx tests with immunohistochemistry/fluorescence in situ hybridization. However, amplification was newly detected in 4 mutations and examples were detected in five HER2\bad breasts tumor examples. Oncogenic mutations had been within three examples with F1CDx among 27 germline tests\negative examples. The mean TMB in every examples was 6.28?mut/Mb and tended…